What does the Deputy Director of Pharmacy say about the death of a 39-year-old woman from thrombosis

A response from the European Medicines Agency (EMA) will await the competent services regarding the death of the 39-year-old who presented with a severe thrombosis. An answer that will essentially say whether the death is connected with the vaccination of the 39-year-old with the AstraZeneca preparation.

Speaking on Radio Proto's First Program, the Deputy Director of Pharmaceutical Services, Elena Panagiotopoulou, explained that EMA's response is not individual.

"The answer will come to be correlated and identified, to compare other cases of other countries. EMA evaluates the cases, evaluates each case separately, sees if there is a comparison (age, how many days later it presented the thrombosis, etc.) to conclude a correlation. "If it comes to a correlation, then it takes measures to minimize the risk so that any side effects are manageable," he said.

He added that, Coreper will give a total correlation answer for a number of incidents. "If there is a correlation between them, he will take action."

If in the first dose there is no thrombosis and they should put the second dose. If they develop a thrombosis do not proceed to their next dose, it is the message of Mrs. Panayotopoulou to people who were vaccinated with the AsrtaZeneca vaccine.

Asked if there are any thoughts from the services to stop the administration of AstraZeneca under the age of 40, Ms. Panagiotopoulou said that the issue is being monitored. "However, Coreper does not impose age restrictions on their marketing authorization. "He recommends and does not impose his decisions, so there are countries that are different," he commented.

Source: Sigmalive